Column Capital Advisors’s Pacira BioSciences PCRX Stock Holding History

Column Capital Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-349	Closed	-$20K	–	739
2022 Q2	$20K	Hold	349	–	–	﹤0.01%	390
2022 Q1	$27K	Buy	349 +133	+62%	+$8.87K	﹤0.01%	370
2021 Q4	$13K	Hold	216	–	–	﹤0.01%	483
2021 Q3	$12K	Hold	216	–	–	﹤0.01%	453
2021 Q2	$13K	Hold	216	–	–	﹤0.01%	444
2021 Q1	$15K	Hold	216	–	–	﹤0.01%	407
2020 Q4	$13K	Hold	216	–	–	﹤0.01%	429
2020 Q3	$13K	Buy	+216	New	+$12.6K	﹤0.01%	406

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Column Capital Advisors's PCRX Position: Q3 2022 in Review

Column Capital Advisors sold out of Pacira BioSciences (PCRX) in Q3 2022, closing a stake of 349 shares — an estimated $20K sold.

Column Capital Advisors first reported a position in PCRX in Q3 2020 and held it in 8 quarters. The position peaked at $27K in Q1 2022. 273 funds tracked by Wall St. Rank hold PCRX as of Q3 2022.

Column Capital Advisors reported no remaining Pacira BioSciences position as of Q3 2022 after selling out during the quarter.
Column Capital Advisors sold 349 Pacira BioSciences shares in Q3 2022, an estimated $20K.
Column Capital Advisors first reported a position in Pacira BioSciences in Q3 2020 and held it in 8 quarters.
Column Capital Advisors's Pacira BioSciences position peaked at $27K in Q1 2022.
273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2022.

Based on Column Capital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.